Loading stock data…
$4.04-0.25 (-5.83%)
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.
Bolt Biotherapeutics, Inc. in the Healthcare sector is trading at $4.04 with a market capitalization of $7M. Wall Street consensus targets $29.00 (3 analysts), implying a +618.7% move over the next 12 months. The stock is currently 44% below its 52-week high of $7.20, remaining 11.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5,000↓ | $26,000↓ | $2.50M↑ | $2.17M↑ | $1.80M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.57M↑ | -$7.60M↓ | -$5.61M↑ | -$7.70M↑ | -$9.21M |
| Net Income | -$7.72M↓ | -$7.24M↓ | -$6.63M↑ | -$7.14M↑ | -$8.56M |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated an...